Jan Oldenburg

• Cornford, Philip; Bergh, Roderick C.N. van den; Briers, Erik; Chiu, Peter; Eberli, Daniel & Epure, Adina [Show all 27 contributors for this article] (2026). EAU–EANM–ESTRO–ESUR–ISUP–SIOG Guidelines on Prostate Cancer—2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology. ISSN 0302-2838. doi: 10.1016/j.eururo.2026.04.013. Full text in Research Archive
• Tilki, Derya; Bergh, Roderick C.N. van den; Briers, Erik; Chiu, Peter; Eberli, Daniel & Epure, Adina [Show all 27 contributors for this article] (2026). EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2026 Update: Treatment of Relapsing and Metastatic Prostate Cancer. European Urology. ISSN 0302-2838. 90(3), p. 270–290. doi: 10.1016/j.eururo.2026.04.014. Full text in Research Archive
• Ferreira, Nádia Gonçalves; Thomas, Owen Matthew Truscott; Gjesdal, Kjell Inge; Müller, Stig; Oldenburg, Jan & Syversen, Ingrid Framås [Show all 8 contributors for this article] (2026). Artificial intelligence in prostate MRI: Comparative diagnostic performance in a high-prevalence cohort. Acta Radiologica. ISSN 0284-1851. doi: 10.1177/02841851261470455. Full text in Research Archive
• Agarwal, Neeraj; Azad, Arun A.; Carles, Joan; Fay, André P.; Matsubara, Nobuaki & Szczylik, Cezary [Show all 21 contributors for this article] (2026). A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer. Future Oncology. ISSN 1479-6694. 22(14), p. 1687–1702. doi: 10.1080/14796694.2026.2661093. Full text in Research Archive
• Galsky, Matthew D.; Heijden, Michiel S. van der; Powles, Thomas; Claps, Melanie; Burotto, Mauricio & Schenker, Michael [Show all 20 contributors for this article] (2025). Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial. European Urology. ISSN 0302-2838. 88(4), p. 325–330. doi: 10.1016/j.eururo.2025.04.019. Full text in Research Archive
• Wilpe, Sandra van; Taha, Tarek; Rothmann, Emily C.; Altshuler, Ellery; Park, Joe & Ledet, Elisa M. [Show all 25 contributors for this article] (2025). Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer. European Urology Oncology (EUO). 8(4), p. 1020–1029. doi: 10.1016/j.euo.2025.04.016. Full text in Research Archive
• Fay, Andre P.; Fizazi, Karim; Matsubara, Nobuaki; Azad, Arun A.; Saad, Fred & Giorgi, Ugo De [Show all 19 contributors for this article] (2025). First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial. The Lancet Oncology. ISSN 1470-2045. 26(4), p. 481–490. doi: 10.1016/S1470-2045(25)00031-2. Full text in Research Archive
• Matsubara, Nobuaki; Azad, Arun A.; Agarwal, Neeraj; Saad, Fred; Giorgi, Ugo De & Joung, Jae Young [Show all 19 contributors for this article] (2025). First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial. The Lancet Oncology. ISSN 1470-2045. 26(4), p. 470–480. doi: 10.1016/S1470-2045(25)00030-0. Full text in Research Archive
• Crippa, Alessio; Laere, Bram De; Discacciati, Andrea; Larsson, Berit; Persson, Maria & Johansson, Susanne [Show all 34 contributors for this article] (2025). Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial. European Urology Oncology (EUO). 8(6), p. 1486–1495. doi: 10.1016/j.euo.2025.02.002. Full text in Research Archive
• Fizazi, Karim; Azad, Arun A.; Matsubara, Nobuaki; Carles, Joan; Fay, André P. & Giorgi, Ugo De [Show all 20 contributors for this article] (2025). Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. The Lancet. ISSN 0140-6736. 406(10502), p. 461–474. doi: 10.1016/S0140-6736(25)00683-X. Full text in Research Archive
• Agarwal, Neeraj; Azad, Arun A.; Carles, Joan; Fay, André P.; Matsubara, Nobuaki & Szczylik, Cezary [Show all 21 contributors for this article] (2025). Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. The Lancet. ISSN 0140-6736. 406(10502), p. 447–460. doi: 10.1016/S0140-6736(25)00684-1. Full text in Research Archive
• Puco, Katarina; Notland, Cathrine S.; Szulkin, Robert; Jonasson, Christian; Beisland, Christian & Johannessen, Tom Børge [Show all 9 contributors for this article] (2025). Overall Survival of Patients with Metastatic Renal Cell Carcinoma Following the Introduction of Targeted and Immunotherapies: A Norwegian Retrospective, Real-World Registry Data Study (RECON3). Cancer Management and Research. 17, p. 103–112. doi: 10.2147/CMAR.S484947. Full text in Research Archive Show summary

  Purpose: In Norway, 5-year survival rates of patients with renal cell carcinoma (RCC) are increasing. The objective of this study was to describe the survival of real-world patients with metastatic RCC (mRCC) across Norway and to identify associated factors. The results may provide additional information on the benefits of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) in clinical practice. Patients and methods: We performed a longitudinal, retrospective, non-interventional cohort study using data from four national registries. The study included adults diagnosed with mRCC between 1 January 1995 and 31 December 2018. Primary endpoint was to evaluate overall survival (OS) in all included patients. Secondary endpoints included further analysis of treatment patterns and possible impact on OS. Secondary endpoint analysis was performed in patients diagnosed with mRCC between 1 January 2008 and 31 December 2018, as complete data on systemic therapies were available from 2008 and onwards. Results: In total, 4078 patients were diagnosed with mRCC in the period from 1995 to 2018. The median OS since initial mRCC diagnosis was 1.17 years. OS appeared to improve over time, 5-year OS was 10% in patients diagnosed in the period 1995-2001 compared to 25% in 2012-2015. The secondary analysis included 2338 patients. Fifty-five percent (55%) of the patients received systemic treatment. No differences were observed in the number of treatment lines administered over time or in the number of lines of treatment administered according to tumor histology. Among 343 patients who received ≥3 treatment lines, we observed longer OS in patients who received an ICI as a part of their treatment, with a median OS of 4.51 compared to 2.31 years. Conclusion: Provision of information into registries is mandatory in Norway. This retrospective, registry-based study provides real-world evidence on patient outcomes and treatments of the Norwegian patients with mRCC in the period from 1995 to 2018.

• Cornford, Philip; Bergh, Roderick C.N. van den; Briers, Erik; Broeck, Thomas Van den; Brunckhorst, Oliver & Darraugh, Julie [Show all 31 contributors for this article] (2024). EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology. ISSN 0302-2838. 86(2), p. 148–163. doi: 10.1016/j.eururo.2024.03.027. Full text in Research Archive
• Azad, Arun A.; Fizazi, Karim; Matsubara, Nobuaki; Saad, Fred; Giorgi, Ugo De & Joung, Jae Young [Show all 19 contributors for this article] (2024). Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study. European Journal of Cancer. ISSN 0959-8049. 213. doi: 10.1016/j.ejca.2024.115078. Full text in Research Archive
• Laere, Bram De; Crippa, Alessio; Discacciati, Andrea; Larsson, Berit; Persson, Maria & Johansson, Susanne [Show all 43 contributors for this article] (2024). Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial. Nature Medicine. ISSN 1078-8956. 30, p. 3291–3302. doi: 10.1038/s41591-024-03204-2. Full text in Research Archive
• Tilki, Derya; Bergh, Roderick C.N. van den; Briers, Erik; Broeck, Thomas Van den; Brunckhorst, Oliver & Darraugh, Julie [Show all 31 contributors for this article] (2024). EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. European Urology. ISSN 0302-2838. 86(2), p. 164–182. doi: 10.1016/j.eururo.2024.04.010. Full text in Research Archive
• Agarwal, Neeraj; Azad, Arun A; Carles, Joan; Fay, Andre P; Matsubara, Nobuaki & Heinrich, Daniel [Show all 21 contributors for this article] (2023). Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. The Lancet. ISSN 0140-6736. 402(10398), p. 291–303. doi: 10.1016/S0140-6736(23)01055-3. Full text in Research Archive Show summary

  Background: Co-inhibition of poly(ADP-ribose) polymerase (PARP) and androgen receptor activity might result in antitumour efficacy irrespective of alterations in DNA damage repair genes involved in homologous recombination repair (HRR). We aimed to compare the efficacy and safety of talazoparib (a PARP inhibitor) plus enzalutamide (an androgen receptor blocker) versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC). Methods: TALAPRO-2 is a randomised, double-blind, phase 3 trial of talazoparib plus enzalutamide versus placebo plus enzalutamide as first-line therapy in men (age ≥18 years [≥20 years in Japan]) with asymptomatic or mildly symptomatic mCRPC receiving ongoing androgen deprivation therapy. Patients were enrolled from 223 hospitals, cancer centres, and medical centres in 26 countries in North America, Europe, Israel, South America, South Africa, and the Asia-Pacific region. Patients were prospectively assessed for HRR gene alterations in tumour tissue and randomly assigned (1:1) to talazoparib 0·5 mg or placebo, plus enzalutamide 160 mg, administered orally once daily. Randomisation was stratified by HRR gene alteration status (deficient vs non-deficient or unknown) and previous treatment with life-prolonging therapy (docetaxel or abiraterone, or both: yes vs no) in the castration-sensitive setting. The sponsor, patients, and investigators were masked to talazoparib or placebo, while enzalutamide was open-label. The primary endpoint was radiographic progression-free survival (rPFS) by blinded independent central review, evaluated in the intention-to-treat population. Safety was evaluated in all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov (NCT03395197) and is ongoing. Findings: Between Jan 7, 2019, and Sept 17, 2020, 805 patients were enrolled and randomly assigned (402 to the talazoparib group and 403 to the placebo group). Median follow-up for rPFS was 24·9 months (IQR 21·9-30·2) for the talazoparib group and 24·6 months (14·4-30·2) for the placebo group. At the planned primary analysis, median rPFS was not reached (95% CI 27·5 months-not reached) for talazoparib plus enzalutamide and 21·9 months (16·6-25·1) for placebo plus enzalutamide (hazard ratio 0·63; 95% CI 0·51-0·78; p<0·0001). In the talazoparib group, the most common treatment-emergent adverse events were anaemia, neutropenia, and fatigue; the most common grade 3-4 event was anaemia (185 [46%] of 398 patients), which improved after dose reduction, and only 33 (8%) of 398 patients discontinued talazoparib due to anaemia. Treatment-related deaths occurred in no patients in the talazoparib group and two patients (<1%) in the placebo group. Interpretation: Talazoparib plus enzalutamide resulted in clinically meaningful and statistically significant improvement in rPFS versus standard of care enzalutamide as first-line treatment for patients with mCRPC. Final overall survival data and additional long-term safety follow-up will further clarify the clinical benefit of the treatment combination in patients with and without tumour HRR gene alterations.

• Bjerner, Lars; Bratt, Ola; Aas, Kirsti; Albertsen, Peter C.; Fosså, Sophie D. & Kvåle, Rune [Show all 16 contributors for this article] (2023). Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death—Results from the Norwegian Prostate Cancer Consortium. European Urology. ISSN 0302-2838. p. 1–7. doi: 10.1016/j.eururo.2023.04.028. Full text in Research Archive Show summary

  Background Prostate-specific antigen (PSA) levels in midlife are strongly associated with the long-term risk of lethal prostate cancer in cohorts not subject to screening. This is the first study evaluating the association between PSA levels drawn as part of routine medical care in the Norwegian population and prostate cancer incidence and mortality. Objective To determine the association between midlife PSA levels <4.0 ng/ml, drawn as part of routine medical care, and long-term risk of prostate cancer death. Design, setting, and participants The Norwegian Prostate Cancer Consortium collected >8 million PSA results from >1 million Norwegian males ≥40 yr of age. We studied 176 099 men (predefined age strata: 40–54 and 55–69 yr) without a prior prostate cancer diagnosis who had a nonelevated baseline PSA level (<4.0 ng/ml) between January 1, 1995 and December 31, 2005. Intervention Baseline PSA. Outcome measurements and statistical analysis We assessed the 16-yr risk of prostate cancer mortality. We calculated the discrimination (C-index) between predefined PSA strata (<0.5, 0.5–0.9, 1.0–1.9, 2.0–2.9, and 3.0–3.9 ng/ml) and subsequent prostate cancer death. Survival curves were plotted using the Kaplan-Meier method. Results and limitations The median follow-up time of men who did not get prostate cancer was 17.9 yr. Overall, 84% of men had a baseline PSA level of <2.0 ng/ml and 1346 men died from prostate cancer, with 712 deaths (53%) occurring in the 16% of men with the highest baseline PSA of 2.0–3.9 ng/ml. Baseline PSA levels were associated with prostate cancer mortality (C-index 0.72 for both age groups, 40–54 and 55–69 yr). The fact that the reason for any given PSA measurement remains unknown represents a limitation. Conclusions We replicated prior studies that baseline PSA at age 40–69 yr can be used to stratify a man's risk of dying from prostate cancer within the next 15–20 yr. Patient summary A prostate-specific antigen level obtained as part of routine medical care is strongly associated with a man’s risk of dying from prostate cancer in the next two decades. Keywords Prostate cancerScreeningProstate-specific antigen

• Fizazi, Karim; Azad, Arun A.; Matsubara, Nobuaki; Carles, Joan; Fay, Andre P. & Giorgi, Ugo De [Show all 21 contributors for this article] (2023). First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine. ISSN 1078-8956. 30(1), p. 257–264. doi: 10.1038/s41591-023-02704-x. Full text in Research Archive
• Albertsen, Peter C.; Bjerner, Lars Johan; Pasovic, Lara; Müller, Stig; Fosså, Sophie Dorothea & Carlsson, Sigrid V. [Show all 7 contributors for this article] (2023). Opportunistic prostate-specific antigen testing in Norwegian men: a public health challenge. BJU International. ISSN 1464-4096. 133(1), p. 104–111. doi: 10.1111/bju.16211. Full text in Research Archive
• Patrikidou, Anna; Cazzaniga, Walter; Berney, Daniel; Boormans, Joost; Angst, Isabel de & Nardo, Domenico Di [Show all 19 contributors for this article] (2023). European Association of Urology Guidelines on Testicular Cancer: 2023 Update. European Urology. ISSN 0302-2838. 84(3), p. 289–301. doi: 10.1016/j.eururo.2023.04.010. Full text in Research Archive
• Heijden, Michiel S. Van Der; Sonpavde, Guru; Powles, Thomas; Necchi, Andrea; Burotto, Mauricio & Schenker, Michael [Show all 24 contributors for this article] (2023). Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. New England Journal of Medicine. ISSN 0028-4793. 389(19), p. 1778–1789. doi: 10.1056/NEJMoa2309863. Full text in Research Archive
• Oldenburg, Jan; Berney, D.M.; Bokemeyer, C.; Climent, Miguel Angel; Daugaard, G. & Gietema, Jourik A. [Show all 13 contributors for this article] (2022). Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. ISSN 0923-7534. 33(4), p. 362–375. doi: 10.1016/j.annonc.2022.01.002. Full text in Research Archive
• Karttunen, Eemil; Hervonen, Petteri; Aliabad, Abolfazl Hosseini; Oldenburg, Jan; Pappot, Helle & Sairanen, Jukka [Show all 13 contributors for this article] (2022). Incidence, mortality and relative survival of patients with cancer of the bladder and upper urothelial tract in the Nordic countries between 1990 and 2019. Scandinavian Journal of Urology. ISSN 2168-1805. 57(1-6), p. 15–21. doi: 10.1080/21681805.2022.2138965. Full text in Research Archive
• Tahiri, Andliena; Puco, Katarina; Naji, Faris; Kristensen, Vessela N.; Alfsen, G. Cecilie & Farkas, Lorant [Show all 10 contributors for this article] (2022). Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors. OncoTarget. 13(1), p. 970–981. doi: 10.18632/oncotarget.28257. Full text in Research Archive Show summary

  Kinase activity is frequently altered in renal cell carcinoma (RCC), and tyrosine kinase inhibitors (TKIs) are part of the standard treatment strategy in patients with metastatic disease. However, there are still no established biomarkers to predict clinical benefits of a specific TKI. Here, we performed protein tyrosine kinase (PTK) profiling using PamChip® technology. The aim of this study was to identify differences in PTK activity between normal and malignant kidney tissue obtained from the same patient, and to investigate the inhibitory effects of TKIs frequently used in the clinics: sunitinib, pazopanib, cabozantinib and tivozanib. Briefly, our results showed that 36 kinase substrates differs (FDR < 0.05) between normal and cancer kidney tissue, where members of the Src family kinases and the phosphoinositide-3-kinase (PI3K) pathway exhibit high activity in renal cancer. Furthermore, ex vivo treatment of clear cell RCC with TKIs revealed that pathways such as Rap1, Ras and PI3K pathways were strongly inhibited, whereas the neurotrophin pathway had increased activity upon TKI addition. In our assay, tivozanib and cabozantinib exhibited greater inhibitory effects on PTK activity compared to sunitinib and pazopanib, implying they might be better suitable as TKIs for selected RCC patients.

• Kaufmann, Ernest; Antonelli, Luca; Albers, Peter; Cary, Clint; Sommer, Silke Gillessen & Heidenreich, Axel [Show all 11 contributors for this article] (2022). Oncological Follow-up Strategies for Testicular Germ Cell Tumours: A Narrative Review. European Urology Open Science. ISSN 2666-1691. 44, p. 142–149. doi: 10.1016/j.euros.2022.08.014. Full text in Research Archive Show summary

  Context The aim of this review is to describe the proportion of testicular germ cell tumours (tGCTs) with recurrence, and the timing and anatomical sites of relapse across different disease stages and after different treatment options. We summarise published follow-up protocols and discuss current and future developments to personalise follow-up for patients with tGCT. Evidence acquisition A systematic literature search was conducted and current guidelines and selected institutional follow-up protocols were reviewed. Evidence synthesis Of 302 publications, we screened 68 full texts and included 29 studies; 22 of these were retrospective and seven were prospective in nature, contributing data for 20 570 patients. The number of patients included per study ranged from 119 to 2483. We compared the guideline follow-up protocols of the European Society for Medical Oncology, European Association of Urology, National Comprehensive Cancer Network, and American Urological Association, as well as institutional follow-up protocols. The protocols differed in terms of the number, time points, and type of follow-up investigations. Conclusions Future research should assess how tGCT can be followed to ensure high adherence, define the role of miR-371a-3p microRNA during follow-up, and develop follow-up protocols after curative treatment in the metastatic setting. Patient summary In this review of follow-up protocols for men with testis cancer, we observed different recommendations and discuss future research areas to improve follow-up for these patients.

• Aeppli, Stefanie; Schmaus, Martina C.; Eisen, Timothy; Escudier, Bernard; Grünwald, Viktor & Larkin, James [Show all 14 contributors for this article] (2021). First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. ESMO Open. 6(1). doi: 10.1016/j.esmoop.2020.100030. Full text in Research Archive Show summary

  Background The treatment landscape of metastatic clear cell renal cell carcinoma (mccRCC) has been transformed by targeted therapies with tyrosine kinase inhibitors (TKI) and more recently by the incorporation of immune checkpoint inhibitors (ICI). Today, a spectrum of single agent TKI to TKI/ICI and ICI/ICI combinations can be considered and the choice of the best regimen is complex. Materials and methods We performed an updated decision-making analysis among 11 international kidney cancer experts. Each expert provided their treatment strategy and relevant decision criteria in the first line treatment of mccRCC. After the collection of all input a list of unified decision criteria was determined and compatible decision trees were created. We used a methodology based on diagnostic nodes, which allows for an automated cross-comparison of decision trees, to determine the most common treatment recommendations as well as deviations. Results Diverse parameters were considered relevant for treatment selection, various drugs and drug combinations were recommended by the experts. The parameters, chosen by the experts, were performance status, International Metastatic renal cell carcinoma Database Consortium (IMDC) risk group, PD-L1 status, zugzwang and contraindication to immunotherapy. The systemic therapies selected for first line treatment were sunitinib, pazopanib, tivozanib, cabozantinib, ipilimumab/nivolumab or pembrolizumab/axitinib. Conclusion A wide spectrum of treatment recommendations based on multiple decision criteria was demonstrated. Significant inter-expert variations were observed. This demonstrates how data from randomized trials are implemented differently when transferred into daily practice.

• Skalleberg, Jakob Rasmussen; Småstuen, Milada Cvancarova; Oldenburg, Jan; Osnes, Terje; Fosså, Sophie Dorothea & Bunne, Bodil Iris Marie (2020). The relationship between cisplatin-related and age-related hearing loss during an extended follow-up. The Laryngoscope. ISSN 0023-852X. 130(9), p. E515–E521. doi: 10.1002/lary.28543. Full text in Research Archive
• Witjes, J. Alfred; Babjuk, Marek; Bellmunt, Joaquim; Bruins, Bruins Maxim; Reijke, Theo M. De & Santis, Maria De [Show all 121 contributors for this article] (2020). EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort^†[Formula presented]: Under the Auspices of the EAU-ESMO Guidelines Committees. European Urology. ISSN 0302-2838. 77(2), p. 223–250. doi: 10.1016/j.eururo.2019.09.035. Full text in Research Archive
• Crippa, Alessio; Laere, Bram De; Discacciati, Andrea; Larsson, Berit; Connor, Jason T. & Gabriel, Erin E. [Show all 16 contributors for this article] (2020). The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer. Trials. 21(1), p. 579–579. doi: 10.1186/s13063-020-04515-8. Full text in Research Archive Show summary

  Background Multiple therapies exist for patients with metastatic castration-resistant prostate cancer (mCRPC). However, their improvement on progression-free survival (PFS) remains modest, potentially explained by tumor molecular heterogeneity. Several prognostic molecular biomarkers have been identified for mCRPC that may have predictive potential to guide treatment selection and prolong PFS. We designed a platform trial to test this hypothesis. Methods The Prostate-Biomarker (ProBio) study is a multi-center, outcome-adaptive, multi-arm, biomarker-driven platform trial for tailoring treatment decisions for men with mCRPC. Treatment decisions in the experimental arms are based on biomarker signatures defined as mutations in certain genes/pathways suggested in the scientific literature to be important for treatment response in mCRPC. The biomarker signatures are determined by targeted sequencing of circulating tumor and germline DNA using a panel specifically designed for mCRPC. Discussion Patients are stratified based on the sequencing results and randomized to either current clinical practice (control), where the treating physician decides treatment, or to molecularly driven treatment selection based on the biomarker profile. Outcome-adaptive randomization is implemented to early identify promising treatments for a biomarker signature. Biomarker signature-treatment combinations graduate from the platform when they demonstrate 85% probability of improving PFS compared to the control arm. Graduated combinations are further evaluated in a seamless confirmatory trial with fixed randomization. The platform design allows for new drugs and biomarkers to be introduced in the study. Conclusions The ProBio design allows promising treatment-biomarker combinations to quickly graduate from the platform and be confirmed for rapid implementation in clinical care. Trial registration ClinicalTrials.gov Identifier NCT03903835. Date of registration: April 4, 2019. Status: Recruiting.

• Aeppli, Stefanie; Eboulet, Eric Innocents; Eisen, Timothy; Escudier, Bernard; Fischer, Stefanie & Larkin, James [Show all 15 contributors for this article] (2020). Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. ESMO Open. 5(3). doi: 10.1136/esmoopen-2020-000852. Full text in Research Archive
• Horwich, Alan; Babjuk, M; Bellmunt, J; Bruins, HM; Reijke, T M De & Santis, M De [Show all 121 contributors for this article] (2019). EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. Annals of Oncology. ISSN 0923-7534. 30(11), p. 1697–1727. doi: 10.1093/annonc/mdz296. Full text in Research Archive
• Normann, Marius; Turzer, Martin; Diep, Lien My; Oldenburg, Jan; Gajdzik, Beata & Popova, Olesya [Show all 7 contributors for this article] (2019). Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer. Journal of Gynecologic Oncology (JGO). ISSN 2005-0380. 30(4), p. 1–10. doi: 10.3802/jgo.2019.30.e56. Full text in Research Archive
• Williams, Stephen B.; Ray-Zack, Mohamed D.; Hudgins, Hogan K.; Oldenburg, Jan; Trinh, Quoc-Dien & Nguyen, Paul L. [Show all 10 contributors for this article] (2019). Impact of centralizing care for genitourinary malignancies to high-volume providers: A systematic review. European Urology Oncology (EUO). 2(3), p. 265–273. doi: 10.1016/j.euo.2018.10.006. Full text in Research Archive
• Honecker, F; Aparicio, J; Berney, D; Beyer, J; Bokemeyer, C & Cathomas, R [Show all 36 contributors for this article] (2018). ESMO consensus conference on testicular germ cell cancer: Diagnosis, treatment and follow-up. Annals of Oncology. ISSN 0923-7534. 29(8), p. 1658–1686. doi: 10.1093/annonc/mdy217. Full text in Research Archive
• Hjelle, Line Veronika; Gundersen, Per Ole Mobråten; Hellesnes, Ragnhild; Sprauten, Mette; Brydøy, Marianne & Tanstad, Torgrim [Show all 11 contributors for this article] (2018). Long-term serum platinum changes and their association with cisplatin-related late effects in testicular cancer survivors. Acta Oncologica. ISSN 0284-186X. 57(10), p. 1392–1400. doi: 10.1080/0284186X.2018.1473641. Full text in Research Archive
• Boormans, Joost L.; Castro, Javier Mayor de; Marconi, Lorenzo; Yuan, Yuhong; Pes, M. Pilar Laguna & Bokemeyer, Carsten [Show all 10 contributors for this article] (2018). Testicular tumour size and rete testis invasion as prognostic factors for the risk of relapse of clinical stage I seminoma testis patients under surveillance: a systematic review by the Testicular Cancer Guidelines panel. European Urology. ISSN 0302-2838. 73(3), p. 394–405. doi: 10.1016/j.eururo.2017.09.025. Full text in Research Archive
• Beisland, Christian; Johannessen, Tom Børge; Klepp, Olbjørn; Axcrona, Ulrika; Torgersen, Knut Martin & Kowalski, Jan [Show all 9 contributors for this article] (2017). Overall Survival in Renal Cell Carcinoma after Introduction of Targeted Therapies: A Norwegian Population-Based Study. OncoTargets and Therapy. 10, p. 371–385. doi: 10.2147/OTT.S123061. Full text in Research Archive Show summary

  Background: This population-wide retrospective, non-interventional registry study assessed changes in overall survival (OS) and factors influencing OS in Norwegian patients with renal cell carcinoma (RCC). Methods: Two population-wide health registries were used to identify all RCC patients with (mRCC) or without metastases diagnosed before (2002–2005) and after (2006–2008 and 2009–2011) introduction of targeted therapies. Median OS was estimated using Kaplan–Meier method. Cox proportional hazards regression modeling was used to identify prognostic factors. Results: Overall, 5,463 patients were diagnosed with RCC during 2002–2005 (n=1,898), 2006–2008 (n=1,631), and 2009–2011 (n=1,934); of these, 1,678 (31%) had mRCC. Patients diagnosed in 2009–2011 and 2006–2008 had significant (P<0.001) improvements in OS versus those diagnosed in 2002–2005: median OS, not reached and not reached versus 82.0 months in RCC; 14.0 and 12.0 months versus 9.0 months in mRCC. Similarly, OS improvements were seen in the primary and elderly (≥75 years) mRCC populations. Median OS was comparable (12 months) between clear cell and papillary mRCC, but it was longer (24.0 months) for chromophobe mRCC. Multivariate regression analyses showed that younger age, previous nephrectomy, and 1 or more prescriptions of targeted therapy were significantly associated with longer OS in mRCC patients. Conclusion: OS increased in RCC and mRCC patients in Norway between 2002 and 2011 following introduction of targeted therapies.

• Gerwing, Mirjam; Jacobsen, Christine; Dyshlovoy, Sergey; Hauschild, Jessica; Rohlfing, Tina & Oing, Christoph [Show all 12 contributors for this article] (2016). Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells. Journal of Cancer Research and Clinical Oncology. ISSN 0171-5216. 142(9), p. 1979–1994. doi: 10.1007/s00432-016-2204-6. Full text in Research Archive
• Tandstad, Torgrim; Ståhl, Olof; Dahl, Olav; Haugnes, Hege Sagstuen; Håkansson, Ulf & Karlsdottir, Åsa [Show all 17 contributors for this article] (2016). Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: A report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Annals of Oncology. ISSN 0923-7534. 27(7), p. 1299–1304. doi: 10.1093/annonc/mdw164. Full text in Research Archive
• Oldenburg, Jan & Dieckmann, Klaus-Peter (2016). Contralateral biopsies in patients with testicular germ cell tumours: What is the rationale? World Journal of Urology. ISSN 0724-4983. p. 1–6. doi: 10.1007/s00345-016-1945-9. Full text in Research Archive
• Hjelle, Line Veronika; Bremnes, Roy M.; Gundersen, Per Ole Mobråten; Sprauten, Mette; Brydøy, Marianne & Tandstad, Torgrim [Show all 10 contributors for this article] (2016). Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors. Urologic Oncology. ISSN 1078-1439. 34(487), p. e13–e20. doi: 10.1016/j.urolonc.2016.06.012. Full text in Research Archive
• Dahl, Alv A; Østby-Deglum, Marie; Oldenburg, Jan; Bremnes, Roy M.; Dahl, Olav & Klepp, Olbjørn [Show all 8 contributors for this article] (2016). Aspects of posttraumatic stress disorder in long-term testicular cancer survivors: cross-sectional and longitudinal findings. Journal of cancer survivorship. ISSN 1932-2259. 10(5), p. 842–849. doi: 10.1007/s11764-016-0529-4. Full text in Research Archive
• Rothermundt, C.; Rappard, J. von; Eisen, T.; Escudier, B.; Grunwald, V. & Larkin, J. [Show all 13 contributors for this article] (2016). Second-line treatment for metastatic clear cell renal cell cancer: experts’ consensus algorithms. World Journal of Urology. ISSN 0724-4983. p. 1–8. doi: 10.1007/s00345-016-1903-6. Full text in Research Archive
• Oldenburg, Jan; Aparicio, J; Beyer, J.; Cohn-Cedermark, G; Cullen, M & Gilligan, T. [Show all 19 contributors for this article] (2015). Personalizing, not patronizing: The case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. Annals of Oncology. ISSN 0923-7534. 26(5), p. 833–838. doi: 10.1093/annonc/mdu514. Full text in Research Archive
• Albers, Peter; Albrecht, Walter; Algaba, Ferran; Bokemeyer, Carsten; Cohn-Cedermark, Gabriella & Fizazi, Karim [Show all 10 contributors for this article] (2015). Guidelines on testicular cancer: 2015 update. European Urology. ISSN 0302-2838. 68(6), p. 1054–1068. doi: 10.1016/j.eururo.2015.07.044. Full text in Research Archive Show summary

  This is an update of the previous European Association of Urology testis cancer guidelines published in 2011, which included major changes in the diagnosis and treatment of germ cell tumours. Objective To summarise latest developments in the treatment of this rare disease. Recommendations have been agreed within a multidisciplinary working group consisting of urologists, medical oncologists, and radiation oncologists. Evidence acquisition A semi-structured literature search up to February 2015 was performed to update the recommendations. In addition, this document was subjected to double-blind peer review before publication. Evidence synthesis This publication focuses on the most important changes in treatment recommendations for clinical stage I disease and the updated recommendations for follow-up. Conclusions Most changes in the recommendations will lead to an overall reduction in treatment burden for patients with germ cell tumours. In advanced stages, treatment intensification is clearly defined to further improve overall survival rates. Patient summary This is an update of a previously published version of the European Association of Urology guidelines for testis cancer, and includes new recommendations for clinical stage I disease and revision of the follow-up recommendations. Patients should be fully informed of all the treatment options available to them.

• Haugnes, Hege Sagstuen; Oldenburg, Jan & Bremnes, Roy M. (2015). Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors. Urologic Oncology. ISSN 1078-1439. 33(9), p. 399–406. doi: 10.1016/j.urolonc.2014.11.012. Full text in Research Archive
• Hjelle, Line Veronika; Gundersen, Per Ole M.; Oldenburg, Jan; Brydøy, Marianne; Tandstad, Torgrim & Wilsgaard, Tom [Show all 9 contributors for this article] (2015). Long-term platinum retention after platinum-based chemotherapy in testicular cancer survivors: A 20-year follow-up study. Anticancer Research. ISSN 0250-7005. 35(3), p. 1619–1625. Full text in Research Archive
• Sprauten, Mette; Haugnes, Hege Sagstuen; Brydøy, Marianne; Kiserud, Cecilie E.; Tandstad, Torgrim & Bjøro, Trine [Show all 10 contributors for this article] (2015). Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors. Annals of Oncology. ISSN 0923-7534. 26(10), p. 2133–2140. doi: 10.1093/annonc/mdv328. Full text in Research Archive
• Rothermundt, Christian; Bailey, Alexandra; Cerbone, Linda; Eisen, Tim; Escudier, Bernard & Gillessen, Silke [Show all 15 contributors for this article] (2015). Algorithms in the first-line treatment of metastatic clear cell renal cell carcinoma—analysis using diagnostic nodes. The Oncologist. ISSN 1083-7159. 20(9), p. 1028–1035. doi: 10.1634/theoncologist.2015-0145. Full text in Research Archive
• Oldenburg, Jan (2015). Hypogonadism and fertility issues following primary treatment for testicular cancer. Urologic Oncology. ISSN 1078-1439. 33(9), p. 407–412. doi: 10.1016/j.urolonc.2015.01.014. Full text in Research Archive
• Aschim, Elin Leirvoll; Oldenburg, Jan; Kristiansen, Wenche; Giwercman, Aleksander; Witczak, Oliwia & Fosså, Sophie Dorothea [Show all 7 contributors for this article] (2014). Genetic variations associated with the effect of testicular cancer treatment on gonadal hormones. Human Reproduction. ISSN 0268-1161. 29(12), p. 2844–2851. doi: 10.1093/humrep/deu274. Full text in Research Archive
• Sprauten, Mette; Brydøy, Marianne; Haugnes, Hege Sagstuen; Småstuen, Milada Cvancarova; Bjøro, Trine & Berner, Johan [Show all 8 contributors for this article] (2014). Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors. Journal of Clinical Oncology. ISSN 0732-183X. 32(6), p. 571–578. doi: 10.1200/JCO.2013.51.2715. Full text in Research Archive
• Tandstad, Torgrim; Ståhl, Olof; Håkansson, Ulf; Dahl, Olav; Haugnes, Hege Sagstuen & Klepp, Olbjørn [Show all 16 contributors for this article] (2014). One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Annals of Oncology. ISSN 0923-7534. 25(11), p. 2167–2172. doi: 10.1093/annonc/mdu375. Full text in Research Archive
• Tandstad, Torgrim; Solberg, Arne; Håkansson, Ulf; Stahl, Olof; Haugnes, Hege Sagstuen & Oldenburg, Jan [Show all 10 contributors for this article] (2014). Bilateral testicular germ cell tumors in patients treated for clinical stage I non-seminoma within two risk-adapted SWENOTECA protocols. Acta Oncologica. ISSN 0284-186X. 54(4), p. 493–499. doi: 10.3109/0284186X.2014.953256. Full text in Research Archive
• Beyer, Jörg; Albers, P; Altena, R; Aparicio, J; Bokemeyer, C & Busch, J [Show all 59 contributors for this article] (2013). Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Annals of Oncology. ISSN 0923-7534. 24(4), p. 878–888. doi: 10.1093/annonc/mds579. Full text in Research Archive
• Fung, Chunkit; Fosså, Sophie Dorothea; Milano, Michael T.; Oldenburg, Jan & Travis, Lois B. (2013). Solid tumors after chemotherapy or surgery for testicular nonseminoma: A population-based study. Journal of Clinical Oncology. ISSN 0732-183X. 31(30), p. 3807–3814. doi: 10.1200/JCO.2013.50.3409. Full text in Research Archive
• Putora, Paul Martin & Oldenburg, Jan (2013). Swarm-Based Medicine. Journal of Medical Internet Research (JMIR). ISSN 1439-4456. 15(9), p. 3–6. doi: 10.2196/jmir.2452. Full text in Research Archive
• Oldenburg, Jan; Fosså, Sophie Dorothea; Nuver, Janine; Heidenreich, Axel; Schmoll, Hans-Joachim & Bokemeyer, Carsten [Show all 9 contributors for this article] (2013). Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. ISSN 0923-7534. 24, p. 125–132. doi: 10.1093/annonc/mdt304. Full text in Research Archive
• Sprauten, Mette; Darrah, Thomas H; Peterson, Derick R.; Campbell, M Ellen; Hannigan, Robyn E & Cvancarova, Milada [Show all 11 contributors for this article] (2012). Impact of Long-Term Serum Platinum Concentrations on Neuro- and Ototoxicity in Cisplatin-Treated Survivors of Testicular Cancer. Journal of Clinical Oncology. ISSN 0732-183X. 30(3), p. 300–307. doi: 10.1200/JCO.2011.37.4025. Full text in Research Archive
• Haugnes, Hege Sagstuen; Bosl, Geroge J; Boer, Hink; Gietema, Jourik A.; Brydøy, Marianne & Oldenburg, Jan [Show all 9 contributors for this article] (2012). Long term and late effects of germ cell testicular cancer treatment and implications for follow-up. Journal of Clinical Oncology. ISSN 0732-183X. 30(30), p. 3752–3763. doi: 10.1200/JCO.2012.43.4431. Full text in Research Archive
• Bachner, Mark; Loriot, Yohann; Gross-Goupil, Marine; Zucali, Paolo Andrea; Horwich, Alan & Germa-Lluch, Josep Ramon [Show all 22 contributors for this article] (2012). 2-(18)fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Annals of Oncology. ISSN 0923-7534. 23(1), p. 59–64. doi: 10.1093/annonc/mdr052. Full text in Research Archive
• Daneshmand, Siamak; Albers, Peter; Fosså, Sophie Dorothea; Heidenreich, Axel; Kollmannsberger, Christian & Krege, Susan [Show all 9 contributors for this article] (2012). Contemporary Management of Postchemotherapy Testis Cancer. European Urology. ISSN 0302-2838. 62(5), p. 867–876. doi: 10.1016/j.eururo.2012.08.014. Full text in Research Archive
• Oldenburg, Jan; Lorch, Anja & Fosså, Sophie Dorothea (2011). Late Relapse of Germ Cell Tumors. Hematology/Oncology Clinics of North America. ISSN 0889-8588. 25(3), p. 615–+. doi: 10.1016/j.hoc.2011.03.006. Full text in Research Archive
• Fosså, Sophie Dorothea; Småstuen, Milada C; Chen, Linlin; Allan, Annie L.; Oldenburg, Jan & Peterson, Derick R. [Show all 7 contributors for this article] (2011). Adverse Prognostic Factors for Testicular Cancer-Specific Survival: A Population-Based Study of 27,948 Patients. Journal of Clinical Oncology. ISSN 0732-183X. 29(8), p. 963–970. doi: 10.1200/JCO.2010.32.3204. Full text in Research Archive
• Stephenson, Andrew J; Aprikan, Armen G; Gilligan, Timothy D; Oldenburg, Jan; Powles, Tom & Toner, Guy C. [Show all 7 contributors for this article] (2011). Management of Low-stage Nonseminomatous Germ Cell Tumors of Testis: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. Urology. ISSN 0090-4295. 78(4), p. S444–S455. doi: 10.1016/j.urology.2011.02.030. Full text in Research Archive Show summary

  OBJECTIVE To advise urologists and other clinicians on the appropriate management of low-stage (clinical Stage [CS] I, IS, IIA, and IIB) nonseminomatous germ cell tumors of the testis. METHODS A panel was convened of experts from 5 countries. A literature search in MEDLINE was used to identify evidence from relevant studies on the outcome and toxicity of observational, surgical, and chemotherapeutic approaches for low-stage nonseminomatous germ cell tumors to form the basis of the panel's recommendations. RESULTS The panel has recommended the treatment of nonseminomatous germ cell tumors in centers with medical, surgical, and diagnostic expertise in testicular cancer. The cancer-specific survival rate for CS I and CS IIA-IIB should approach 100% and 95%-100%, respectively. Patients with CS I should be made aware of all treatments (ie, surveillance, primary chemotherapy, and retroperitoneal lymph node dissection) and the potential side effects. For patients with CS I at low risk of occult metastasis, surveillance is preferred. For patients at high risk of occult metastasis, all 3 options can be considered. For immediate treatment, the choice between primary chemotherapy and retroperitoneal lymph node dissection should be determined by patient preference and the specific expertise of the treating institution. Patients with increasing postorchiectomy serum alpha-fetoprotein or human choriogonadotropin levels (CS IS and CS IIA-IIB) should receive induction chemotherapy. Induction chemotherapy or retroperitoneal lymph node dissection can be considered for patients with CS IIA-IIB with normal postorchiectomy alpha-fetoprotein and human choriogonadotropin levels. Surveillance can be considered for patients with equivocal computed tomography retroperitoneal findings who are otherwise at low risk of metastatic disease. CONCLUSION These clinical practice guidelines are designed to improve clinical practice from the available evidence and the expert opinion of the panel. As such, deviation from these recommendations should be based on sound clinical judgment, considering the unique situation of the patient and the expertise of the treating physician and institution. UROLOGY 78: S444-S455, 2011. (C) 2011 Elsevier Inc.

• Oldenburg, Jan & Fosså, Sophie D. (2009). Long-term toxicity after therapy for testicular cancer with special focus on sexual disorders. Der Urologe. ISSN 0340-2592. 48(4), p. 372–376. Full text in Research Archive Show summary

  Due to cisplatin-based chemotherapy, the survival rate of testicular cancer patients approaches 90%. Chemo- or radiotherapy may cause long-term complications, e.g. cardiovascular disease, secondary cancers and reduced fertility. Sperm cryopreservation is recommended depending on the extent of therapy and should be performed before orchiectomy. Furthermore, patients should be informed about long-term complications and their possible reduction by optimizing the risk factor profile.

• Oldenburg, Jan & Fosså, Sophie D. (2009). Late relapse of nonseminomatous germ cell tumours. BJU International. ISSN 1464-4096. 104(9B), p. 1413–1417. Full text in Research Archive Show summary

  Late relapses of nonseminomatous cell tumours (NSGCTs) are rare and occur by definition at >= 2 years after successful treatment. They represent a major challenge of current treatment and follow-up of the affected patients. We present relevant literature on late-relapsing NSGCTs to provide an overview over the effect of primary treatment, patient and tumour characteristics. Of all patients with NSGCT, 1-6% have a late relapse, with those having extragonadal GCTs being at greatest risk. The predominant site of relapse is the retroperitoneal space. Suboptimal primary treatment, especially insufficient retroperitoneal surgery, increases the risk of late relapses. Radical surgery is probably the most important treatment, with advances in salvage chemotherapy adding to the improved cure rates. Treatment at an experienced institution ensures a 5-year cancer-specific survival of > 50%, and this approaches 100% in case of single-site mature teratoma. Diagnosis and proper treatment of patients with late-relapsing NSGCTs is challenging and should be restricted to experienced centres only. Referral of late-relapsing patients to high-volume institutions ensures the best chances of cure and enables increasing understanding of tumour biology and the clinical course of these patients.

• Oldenburg, Jan & Fossa, Sofie D (2009). Late relapse of nonseminomatous germ cell tumours. BJU International. ISSN 1464-4096. 104(9B), p. 1413–1417. doi: 10.1111/j.1464-410X.2009.08868.x. Full text in Research Archive
• Oldenburg, Jan; Wahlqvist, Rolf & Fosså, Sophie D. (2009). Late relapse of germ cell tumors. World Journal of Urology. ISSN 0724-4983. 27(4), p. 493–500. Full text in Research Archive Show summary

  Treatment of late relapsing MGCT patients is challenging and should be performed in experienced centers only. Referral of late relapsing patients to high-volume institutions ensures the best chances of cure and enables multimodal treatment, and contributes to increased knowledge of tumor biology as well experience with the clinical course of these patients.

• Brydøy, Marianne; Oldenburg, Jan; Oldenburg, J; Klepp, Olbjørn; Bremnes, Roy M. & Wist, Erik [Show all 11 contributors for this article] (2009). Observational Study of Prevalence of Long-term Raynaud-Like Phenomena and Neurological Side Effects in Testicular Cancer Survivors. Journal of the National Cancer Institute. ISSN 0027-8874. 101(24), p. 1682–1695. doi: 10.1093/jnci/djp413. Full text in Research Archive
• Brydøy, Marianne; Oldenburg, Jan; Klepp, Olbjørn; Bremnes, Roy M.; Wist, E. & Wentzel-Larsen, Tore [Show all 9 contributors for this article] (2009). Observational Study of Prevalence of Long-term Raynaud-Like Phenomena and Neurological Side Effects in Testicular Cancer Survivors. Journal of the National Cancer Institute. ISSN 0027-8874. 101(24), p. 1682–1695. Full text in Research Archive Show summary

  Long-term survivors of testicular cancer who were treated with cisplatin-based chemotherapy were more often troubled by dose-dependent neurological side effects and Raynaud-like phenomena compared with those who were not treated with chemotherapy.

• Kraggerud, Sigrid M.; Oldenburg, Jan; Alnæs, Grethe Irene Grenake; Berg, Marianne; Kristensen, Vessela N. & Fosså, Sophie D. [Show all 7 contributors for this article] (2009). Functional glutathione S-transferase genotypes among testicular germ cell tumor survivors: associations with primary and post-chemotherapy tumor histology. Pharmacogenetics & Genomics. ISSN 1744-6872. 19(10), p. 751–759. Full text in Research Archive Show summary

  Conclusion This study confirms an association between the GSTP1-G-allele and TGCT. Combinations of GST genotypes were associated with primary and post-chemotherapy tumor histology, and prognostic group presentation. Pharmacogenetics and Genomics 19:751-759 (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins.

View all works in NVA

• Fizazi, Karim; Azad, Arun A; Matsubara, Nobuaki; Carles, Joan; Fay, Andre P & Giorgi, Ugo De [Show all 21 contributors for this article] (2025). Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TALAPRO-2 study. Future Oncology. ISSN 1479-6694. 21(6), p. 637–652. doi: 10.1080/14796694.2025.2449754. Full text in Research Archive
• Heijden, Michiel S van der; Sonpavde, Guru; Powles, Thomas; Necchi, Andrea; Burotto, Mauricio & Schenker, Michael [Show all 24 contributors for this article] (2025). Treatment of advanced urothelial cancer with nivolumab plus chemotherapy versus chemotherapy alone (CheckMate 901 study): a plain language summary. Future Oncology. ISSN 1479-6694. 21(6), p. 605–616. doi: 10.1080/14796694.2024.2443355. Full text in Research Archive
• Fizazi, Karim; Azad, Arun A.; Matsubara, Nobuaki; Carles, Joan; Fay, Andre P. & Giorgi, Ugo De [Show all 21 contributors for this article] (2024). Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial (Nature Medicine, (2024), 30, 1, (257-264), 10.1038/s41591-023-02704-x). Nature Medicine. ISSN 1078-8956. doi: 10.1038/s41591-024-02835-9. Full text in Research Archive
• Agarwal, Neeraj; Azad, Arun A.; Carles, Joan; Fay, Andre P.; Matsubara, Nobuaki & Heinrich, Daniel [Show all 21 contributors for this article] (2024). Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer. Future Oncology. ISSN 1479-6694. p. 1–13. doi: 10.1080/14796694.2024.2362108. Full text in Research Archive Show summary

  What is this summary about?: This summary describes the results from the TALAPRO-2 research study (also known as a clinical trial). The TALAPRO-2 study tested the combination of two medicines called talazoparib plus enzalutamide. This combination of medicines was used as the first treatment for adult patients with metastatic castration-resistant prostate cancer. The combination of talazoparib plus enzalutamide was compared with a placebo plus enzalutamide. What is metastatic castration-resistant prostate cancer?: Metastatic castration-resistant prostate cancer is a type of cancer that starts in the prostate and has spread to other parts of the body. Castration-resistant means that the cancer continues to grow even when testosterone levels in the blood are reduced to very low levels. Taking medicines to lower testosterone levels in the blood is a standard treatment for men with advanced prostate cancer. What are the aims of the talapro-2 trial?: TALAPRO-2 looked at if combining talazoparib plus enzalutamide would increase the length of time patients lived before their cancer got worse or they died compared with a placebo plus enzalutamide. Researchers looked at how treatment affected the size and number of tumors and the length of time before patients needed to change to a new cancer medicine. Researchers also looked at any side effects patients had during the study. What are the key takeaways?: A total of 805 patients with metastatic castration-resistant prostate cancer took part in the study. Compared with patients who took a placebo plus enzalutamide, the group of patients who took talazoparib plus enzalutamide had a 37% reduced risk of their cancer getting worse or dying. Some patients had tumors that at the start of the study could be measured with scans. Sixty-two percent of patients who took talazoparib plus enzalutamide had their tumors decrease or shrink to the point that they could no longer be seen on scans versus 44% of patients who took a placebo plus enzalutamide. Patients who took talazoparib plus enzalutamide were more likely to have a longer time before they needed to change to a new cancer medicine. The most common side effects of talazoparib plus enzalutamide were low levels of red blood cells (66% of patients) and neutrophils (36% of patients), and excessive tiredness or exhaustion (34% of patients).Clinical Trial Registration: NCT03395197 (TALAPRO-2) (ClinicalTrials.gov).

• Bjerner, Lars Johan; Bratt, Ola; Aas, Kirsti; Albertsen, Peter C.; Carlsson, Sigrid V. & Oldenburg, Jan (2024). Reply to Rongkang Li, Lei Peng, Shaohua Zhang, and Song Wu's Letter to the Editor re: Johan Bjerner, Ola Bratt, Kirsti Aas, et al. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death—Results from the Norwegian Prostate Cancer Consortium. Eur Urol 2024;86:20–6. European Urology. ISSN 0302-2838. doi: 10.1016/j.eururo.2024.08.034. Full text in Research Archive
• Karttunen, Eemil; Oldenburg, Jan; Thoresen, Steinar Østerbø & Ullén, Anders (2023). Response to M. Brehmer: Register-based research. Accurate data and analysis, crucial for correct conclusions. Comment on 'Incidence, mortality, and relative survival of patients with cancer of the bladder and upper urothelial tract in the Nordic countries between 1990 and 2019'. Scandinavian Journal of Urology. ISSN 2168-1805. 58, p. 20–20. doi: 10.2340/sju.v58.10299. Full text in Research Archive
• Fankhauser, Christian D.; Oldenburg, Jan; Albers, Peter; Algaba, Ferran; Bokemeyer, Carsten & Boormans, Joost L. [Show all 17 contributors for this article] (2021). Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021. European Urology. ISSN 0302-2838. 80(1), p. 4–6. doi: 10.1016/j.eururo.2021.02.032. Full text in Research Archive
• Witjes, J. Alfred; Babjuk, Marek; Bellmunt, Joaquim; Bruins, H. Maxim; Reijke, Theo M. De & Santis, Maria De [Show all 122 contributors for this article] (2020). Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035). European Urology. ISSN 0302-2838. 78(1), p. e48–e50. doi: 10.1016/j.eururo.2020.03.017. Full text in Research Archive
• Heinrich, Daniel; Russnes, Kjell Magne & Oldenburg, Jan (2018). Re: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. European Urology. ISSN 0302-2838. doi: 10.1016/j.eururo.2018.04.010. Full text in Research Archive
• Oldenburg, Jan & Gietema, Jourik A. (2016). The sound of silence: A proxy for platinum toxicity. Journal of Clinical Oncology. ISSN 0732-183X. 34(23), p. 2687–2689. doi: 10.1200/JCO.2016.68.2476. Full text in Research Archive
• Oldenburg, Jan; Haugnes, Hege Sagstuen; Dahl, Olav; Karlsdottir, Åsa; Langberg, Carl W. & Klepp, Olbjørn [Show all 8 contributors for this article] (2015). Behandling ved stadium I-testikkelkreft bør vurderes individuelt. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 135(15), p. 1340–1341. doi: 10.4045/tidsskr.15.0544. Full text in Research Archive
• Oldenburg, Jan & Wit, Ronald de (2015). Primum non nocere: Of course! But how? Journal of Clinical Oncology. ISSN 0732-183X. 33(20), p. 2320–2320. doi: 10.1200/JCO.2015.61.2291. Full text in Research Archive
• Fung, Chunkit; Fosså, Sophie Dorothea; Oldenburg, Jan; Milano, Michael T. & Travis, Lois B. (2014). Reply to G. Gandaglia et al. Journal of Clinical Oncology. ISSN 0732-183X. 32(11), p. 1167–1169. doi: 10.1200/JCO.2013.54.6168. Full text in Research Archive
• Oldenburg, Jan; Cullen, M & Tandstad, Torgrim (2014). Primum non nocere: do we harm stage I testicular cancer patients less by applying adjuvant chemotherapy than by failing to present this option? Annals of Oncology. ISSN 0923-7534. 26(2), p. 255–256. doi: 10.1093/annonc/mdu520. Full text in Research Archive
• Putora, Paul Martin & Oldenburg, Jan (2014). The Kafkaesque process of cancer diagnosis. 32(10), p. 1087–1088. doi: 10.1200/JCO.2013.54.2449. Full text in Research Archive
• Tandstad, Torgrim; Stahl, E.; Dahl, Olav; Haugnes, Hege Sagstuen; Langberg, Carl W. & Laurell, Anna [Show all 13 contributors for this article] (2014). Management of clinical stage I seminomatous testicular cancer: A report from SWENOTECA. Full text in Research Archive
• Sprauten, Mette; Haugnes, Hege Sagstuen; Brydøy, Marianne; Fosså, Sophie Dorothea & Oldenburg, Jan (2013). Impact of testicular scatter radiation (TSR) on testosterone (T) and luteinizing hormone (LH) 11 and 18 years after abdominal radiotherapy for testicular cancer. European Journal of Cancer. ISSN 0959-8049. 49, p. S647–S648. Full text in Research Archive
• Sprauten, Mette; Cvancarova, Milada; Fosså, Sophie Dorothea; Brydøy, Marianne; Haugnes, Hege Sagstuen & Oldenburg, Jan (2012). Longitudinal serum testosterone levels (T) in long-term testicular cancer survivors (TCSs) in relation to testicular cancer (TC) treatment, aging, and TC diagnosis itself. Journal of Clinical Oncology. ISSN 0732-183X. 30(15). Full text in Research Archive
• Tandstad, Torgrim; Solberg, Arne; Håkansson, Ulf; Angelsen, Anders; Haugnes, Hege Sagstuen & Oldenburg, Jan [Show all 9 contributors for this article] (2012). Bilateral testicular cancer within two prospective, population-based SWENOTECA protocols in clinical stage I nonseminoma. Journal of Clinical Oncology. ISSN 0732-183X. 30(15:4508). Full text in Research Archive
• Kersten, Christian; Cameron, Marte G & Oldenburg, Jan (2012). Truth in Hope and Hope in Truth. Journal of Palliative Medicine. ISSN 1096-6218. 15(1), p. 128–129. doi: 10.1089/jpm.2011.0209. Full text in Research Archive
• Oldenburg, Jan & Fosså, Sophie Dorothea (2011). Cancer Survivorship. European Journal of Cancer. ISSN 0959-8049. 47, p. S36–S36. Full text in Research Archive
• Oldenburg, Jan & Gietema, Jourik A. (2011). IT'S TIME TO SYSTEMATICALLY INVESTIGATE BIOMARKERS FOR TREATMENT ALLOCATION OF TESTICULAR CANCER PATIENTS. BJU International. ISSN 1464-4096. 107(6), p. 942–943. doi: 10.1111/j.1464-410X.2010.10004.x. Full text in Research Archive
• Travis, LB; Beard, C; Allan, James; Dahl, Alv A; Feldman, D. & Oldenburg, Jan [Show all 22 contributors for this article] (2010). Testicular Cancer Survivorship: Research Strategies and Recommendations. Journal of the National Cancer Institute. ISSN 0027-8874. 102(15), p. 1114–1130. doi: 10.1093/jnci/djq216. Full text in Research Archive
• Aschim, Elin Leirvoll; Oldenburg, Jan; Kristiansen, Wenche; Fosså, Sophie Dorothea & Haugen, Trine B. (2010). Polymorphisms in CYP genes affect gonadal hormone levels in ≥ 5 years testicular cancer survivors. Full text in Research Archive
• Aschim, Elin Leirvoll; Oldenburg, Jan; Kristiansen, Wenche; Fosså, Sophie Dorothea & Haugen, Trine B. (2010). Polymorphisms in CYP genes affect gonadal hormone levels in ≥ 5 years testicular cancer survivors. Full text in Research Archive
• Sprauten, Mette; Darrah, Thomas H.; Hannigan, Robyn E.; Beard, Clair; Haugnes, Hege Sagstuen & Cvancarova, Milada [Show all 10 contributors for this article] (2010). Long-term accumulation of platinum (Pt) and its impact on self-reported neuro-and ototoxicity in cisplatin-treated testicular cancer survivors (TCSs). European Journal of Cancer. ISSN 0959-8049. 8(5), p. 153–154. Full text in Research Archive
• Oldenburg, Jan & Fosså, Sophie Dorothea (2009). Long-term outcome after treatment for testicular cancer. Universitetet i Oslo. ISSN 9788280723093. Full text in Research Archive

View all works in NVA